AstraZeneca COVID-19 Vaccine Linked To Another Rare Fatal Blood Clotting Disorder VITT

A team of researchers has claimed that British-Swedish pharma giant AstraZeneca's COVID-19 vaccine has been found to raise the risk of VITT or vaccine-induced immune thrombocytopenia and thrombosis, a rare but fatal blood clotting disorder. This came after the company admitted that the vaccine, made in collaboration with Oxford University, can, in very rare cases, cause Thrombotic Thrombocytopenic Syndrome (TTS).